Although sensitivity to gemcitabine has been previously associated with specific genomic alterations (such as ARID1A deficiency) in preclinical models, a genomic biomarker has not been previously associated with clinical response to gemcitabine in ovarian cancer or any other malignancy35. The gene discussed is ARID1A; the disease is ovarian cancer.